Achyut Healthcar (543499)
Fast GrowerScore breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹48 |
| Market Cap | ₹1,187.35 Cr |
| P/E Ratio | 289.23 |
| ROCE | 2.26% |
| ROE | 0.01% |
| Dividend Yield | 0% |
| Profit Growth | -100% |
| Debt/Equity | — |
| Sales Growth | 0% |
| 52-Week Range | ₹4.7 — ₹48 |
| Sector | Pharmaceuticals & Biotechnology |
| Book Value | ₹1.32 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
Let's start by saying this is not the kind of investment I would make. At ₹48, the market capitalisation is ₹1,187 crore, yet the latest quarterly sales were just ₹2 crore. That means the stock trades at an absurd multiple of revenue. The P/E is meaningless at 289, because earnings are effectively zero. Profit growth has collapsed by 100%, and return on equity is 0.01%. When I buy a business, I look for a durable product, a moat, and a management that earns a good return on capital. Here, ROCE is only 2.26%, so even the operational return is pitiful. Book value is ₹1.32 per share, so you're paying 36 times book for a business with no growth in sales and no dividend. The Piotroski score of 3 out of 9 tells me financial health is poor. The 52-week range of ₹4.70 to ₹48 shows speculation, not fundamental value. A stock can go up only so long on hope; eventually earnings must justify the price. In Graham's words, price is what you pay, value is what you get. Here you are paying a fortune for very little value. The only 'strength' is that the company is not shrinking sales at the moment and isn't losing money – but that hardly matters when the price implies a near-perfect future. I would be a seller, not a buyer. If the business ever manages to grow sales from this tiny base, the stock may still be too expensive. Wait for either a much lower price or proven profitability and growth.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer